Curewell Capital, a private equity firm specializing in the enhancement and development of industry-leading middle-market healthcare companies, has proudly announced the successful closing of its inaugural fund, Curewell Capital I. This fund, which reached a hard cap of $535 million, achieved an impressive milestone by completing its fundraising in a single closing event, less than five months after its official launch.
The firm attracted a diverse consortium of global institutional investors, comprising prestigious endowments and foundations, pension funds, insurance companies, industry consultants, family offices, and seasoned executives. This wide-ranging support reflects the strong confidence investors have in Curewell’s vision and strategy.
At the helm of Curewell Capital are Michael Dal Bello and Ceron Rhee, two experienced leaders who share nearly two decades of partnership. Their strong working relationship includes significant tenures at both Blackstone and Pritzker Private Capital, where they expertly led the healthcare investment practice.
Curewell Capital I builds on the accomplished team’s established strategy, which focuses on acquiring and revitalizing leading U.S. healthcare businesses across various sectors, including healthcare services, pharmaceutical services, medical devices, and healthcare technology.
The firm seeks to forge strategic partnerships with knowledgeable founders and management teams who are at the forefront of extraordinary healthcare companies. Through these collaborations, Curewell aims to accelerate growth trajectories and enhance operational performance, ultimately driving innovation and excellence in the healthcare industry.
Advisor/counsel: Probitas Partners acted as the exclusive placement advisor for the fund. And Kirkland & Ellis acted as fund counsel.
KEY QUOTES:
“We are grateful for the trust and support of an exceptional group of investors. We are further honored to work with founders, owners, and management teams who share our vision of increasing access to healthcare, lowering overall system costs, and enhancing quality of care. We look forward to building lasting value together.”
Michael Dal Bello, Co-Founder and Partner
“This fund represents our next chapter in partnering with accomplished teams advancing innovation and transformation in healthcare. We are seeing strong secular tailwinds across our key areas of focus, providing meaningful opportunities for companies to improve outcomes and drive efficiencies throughout the U.S. healthcare system.”
Ceron Rhee, Co-Founder and Partner
